Molecular Diagnostics News and Research

RSS

Diagnosing colonic polyps: an interview with Dr. Haili Wang, Metabolomic Technologies Inc. (MTI)

Colorectal cancer is a leading cause of death in North America, but it is preventable if found at the colonic polyp stage. Currently, only 39% of colorectal cancer cases in the US are diagnosed at an early and treatable stage.

28 Nov 2013

Collaborative initiative set up to create precision medicine treatment pathways for advanced cancers

The Joint Center for Cancer Precision Medicine, a collaborative initiative among Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, and the Broad Institute of MIT and Harvard, has been established to create "precision medicine treatment pathways" for patients with advanced cancers and to speed the development of personalized therapies.

16 Nov 2013

AMP 2013: EKF Molecular Diagnostics to launch four new PointMan DNA enrichment kits

EKF Diagnostics, the global diagnostics business, announces that EKF Molecular Diagnostics will launch four new PointMan DNA enrichment kits.

From EKF Diagnostics 13 Nov 2013

AMP 2013 to focus on genomics, proteomics, informatics, reimbursement and optimization of patient care

AMP will host its largest ever annual meeting next week with an expected attendance of more than 1,700 molecular diagnostic professionals plus 1,300 representatives from more than 180 exhibiting companies. With more than 25 hours of educational sessions and 350 poster presentations, the AMP 2013 Annual Meeting is the premier source for educational information on all things molecular.

5 Nov 2013

New MDx prototype platform can detect BRAF V600 mutations in 90 minutes

A new diagnostic platform to detect BRAF mutations in melanoma and other cancer types is faster and more accurate compared with the standard method currently used in clinics, and this could help accelerate diagnosis and treatment, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

23 Oct 2013

RNA-based gene expression test potentially determine presence or absence of BRAF V600E mutation

Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, today announced preliminary study results suggesting the potential for an RNA-based gene expression test to accurately detect the BRAF V600E gene mutation in thyroid nodule fine needle aspiration (FNA) samples.

19 Oct 2013

King's College researchers identify new biomarker that detects sepsis in blood

Researchers at King's College London have identified a biomarker - a biological 'fingerprint' - for sepsis in the blood, and showed it could be possible to diagnose the condition within two hours by screening for this biomarker at a patient's bedside.

17 Oct 2013

Trovagene launches pharmaceutical alliance to monitor lung cancer patients' EGFR mutational status

Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced that it will collaborate with a pharmaceutical company to evaluate Trovagene's proprietary, urine-based, cell-free DNA technology for the detection of certain epidermal growth factor receptor mutations associated with lung cancer.

16 Oct 2013

Next-generation sequencing technology effective for detecting BRCA1 and BRCA2 mutations

The recognition of a causal link between mutations in BRCA1 and BRCA2 genes and increased risk of developing breast and ovarian cancer has intensified the demand for genetic testing. Identifying mutations in these large genes by conventional methods can be time consuming and costly.

9 Oct 2013

Clinical Genomics Nabs Enterix, Aims To Launch New Bowel Cancer Blood Test

...

8 Oct 2013

Biosearch Technologies Acquires Majority Stake In Lightspeed Genomics

...

26 Sep 2013

Diagnoplex SA sign agreement with Unilabs to commercialize Colox colorectal cancer assay

Diagnoplex SA, a developer of molecular diagnostics for colorectal cancer and Unilabs, a leading supplier of clinical laboratory and medical diagnostic imaging services in Europe, signed a collaboration agreement to commercialize Colox, a minimally invasive colorectal cancer assay within the Unilabs network. The test will be available initially in the Swiss and Swedish markets.

18 Sep 2013

AMP announces slate of award winners for excellent work in molecular pathology

The Association for Molecular Pathology (AMP) proudly announces its slate of award winners for 2013. Each recipient was carefully vetted and selected by a distinguished group of AMP leadership.

17 Sep 2013

Data can help scientists, physicians match precision drugs to cancer's genetic traits

More than 5,000 genetic profiles of tumor DNA have been completed in a large research study by scientists at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Boston Children's Hospital designed to speed the development of personalized cancer care with precision treatments.

13 Sep 2013

S&P Capital IQ commences Standard & Poor's Factual Stock Report coverage on Epigenomics AG

S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Epigenomics AG.

7 Sep 2013

Trovagene, University of Southern California enter into clinical collaboration agreement

Trovagene, Inc., a developer of molecular diagnostics for cancer monitoring, today announced that the Company has entered into a clinical collaboration agreement with the University of Southern California to study genomic characterizations of metastatic colorectal cancers using Trovagene's proprietary cell-free DNA assays.

6 Sep 2013

Researchers develop ddPCR technology to quantify rejection biomarker in organ transplant injury

A recently reported blood test for the early detection of organ transplant injury could enable more timely therapeutic intervention in transplant patients and thus help to avoid longer term damage. As described by scientists at the University Medical Center G-ttingen and Chronix Biomedical, a molecular diagnostics company, the new method uses Bio-Rad Laboratories' Droplet Digital PCR (ddPCR-) technology to overcome the obstacles of earlier tests, which were both time-consuming and costly.

28 Aug 2013

Companion diagnostics: an interview with Trevor Hawkins, SVP, Strategy, Innovation and Business Development for Siemens Healthcare Diagnostics

Companion diagnostics is critical in helping to pave the way for personalized medicine, in which the treatment is adapted and precisely tailored to the patient.

From Siemens Healthineers 27 Aug 2013

Mount Sinai, Exosome Partner On Body Fluid Molecular Diagnostics

...

22 Aug 2013

Genenews Axes 60% Of Staff To Boost New JV

...